Latest research on Darunavir

Darunavir is a protease inhibitor used to treat HIV. It acts on the HIV aspartyl protease which the virus needs to cleave the HIV polyprotein into its functional fragments.

Darunavir interactions

Furthermore, Ethanol exposure significantly decreased the IC50 values of Amprenavir, Darunavir, and nelfinavir but robustly elevated the IC50 of Indinavir and Ritonavir [12, 13], suggesting a differential impact of Ethanol on the binding and bio-transformation of protease inhibitors. [source, 2016]
Tail data in healthy volunteers is available for boosted atazanavir [19,20], boosted Lopinavir once and twice daily [20], boosted Darunavir [19], co-formulated efavirenz/tenofovir/emtricitabine [21], dolutegravir [22], co-formulated elvitegravir/cobicistat/tenofovir/emtricitabine [22] and co-formulated rilpivirine/tenofovir/emtricitabine [23] and is presented in Table 1. [source, 2016]
TDF levels are also raised significantly when co-administered with either cobicistat or three ritonavir-boosted PIs – Lopinavir, Darunavir (DRV) and atazanavir (ATV) [35–39]. [source, 2016]
A minority would replace EFV with raltegravir, Nevirapine, atazanavir or Darunavir, citing potency or concerns about EFV side effects. [source, 2016]
The patient's treatment was switched to Zidovudine, Lamivudine, raltegravir and boosted Darunavir. [source, 2016]
The HARRT regiments were based on 2 reverse transcriptase inhibitors (mainly Combivir, Truvada, or Kivexa) and either a nonnucleoside reverse transcriptase inhibitor (Efaviranze) or a boosted protease inhibitor (mainly Kaletra, boosted Atazanavir, or boosted Darunavir) or an integrase inhibitor (Isentress). [source, 2016]
Subject headings and keywords were tailored for each electronic resource using the following concepts: (atazanavir OR Darunavir OR dolutegravir OR Fosamprenavir OR Indinavir OR Lopinavir OR saquinavir) AND (Efavirenz OR enfuvirtide OR etravirine OR Lamivudine OR maraviroc OR Nevirapine OR raltegravir OR rilpivirine OR saquinavir OR Tenofovir OR tipranavir). [source, 2016]
A study that compared the potency of different PIs against HIV-2 showed that Lopinavir, saquinavir, tipranavir and Darunavir were the most potent [10]. [source, 2016]
Another study reported that saquinavir, Lopinavir and Darunavir are potent inhibitors of HIV-2 isolates [12]. [source, 2016]
We identified eight studies comparing the cost-effectiveness analyses of the specific HAART regimens; two compared Darunavir + low-dose Ritonavir (DRV/r) with Lopinavir + Ritonavir. [source, 2015]